Vaxcyte, Inc.(PCVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PCVX Vaxcyte, Inc.

Not Yet Opened 12-11 16:00:00 EST

44.59

+1.10

+2.53%

盘后44.50

-0.09-0.20%

19:56 EST

High45.15	Low43.44	Vol1.15M
Open43.90	D1 Closing43.49	Amplitude3.93%
Mkt Cap5.84B	Tradable Cap5.22B	Total Shares130.91M
T/O51.22M	T/O Rate0.98%	Tradable Shares116.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PCVX","market":"US","secType":"STK","nameCN":"Vaxcyte, Inc.","latestPrice":44.59,"timestamp":1765486800000,"preClose":43.49,"halted":0,"volume":1151147,"hourTrading":{"tag":"盘后","latestPrice":44.5,"preClose":44.59,"latestTime":"19:56 EST","volume":61865,"amount":2758534.26,"timestamp":1765500972762},"delay":0,"floatShares":116968635,"shares":130906263,"eps":-4.840128,"marketStatus":"Not Yet Opened","change":1.1,"latestTime":"12-11 16:00:00 EST","open":43.9,"high":45.15,"low":43.44,"amount":51215621.317356005,"amplitude":0.039319,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.840128,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765530000000},"marketStatusCode":0,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":43.49,"preHourTrading":{"tag":"盘前","latestPrice":43.66,"preClose":43.49,"latestTime":"09:28 EST","volume":222,"amount":9628.647936,"timestamp":1765463280086},"postHourTrading":{"tag":"盘后","latestPrice":44.5,"preClose":44.59,"latestTime":"19:56 EST","volume":61865,"amount":2758534.26,"timestamp":1765500972762},"volumeRatio":0.892804,"impliedVol":0.5274,"impliedVolPercentile":0.092},"requestUrl":"/m/hq/s/PCVX/tweets","defaultTab":"tweets","newsList":[{"id":"2590322194","title":"Vaxcyte (PCVX): Reassessing Valuation After OPUS Phase 3 Trial Start for Next-Generation Pneumococcal Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2590322194","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590322194?lang=en_us&edition=fundamental","pubTime":"2025-12-10 01:28","pubTimestamp":1765301329,"startTime":"0","endTime":"0","summary":"Vaxcyte (PCVX) just hit a key milestone by dosing the first participants in its OPUS Phase 3 trial of VAX-31, a head-to-head study against current adult pneumococcal vaccines that supports its future approval plans.\nSee our latest analysis for Vaxcyte.\nThat backdrop helps explain why, even with a sharp year to date share price return of minus 44.56 percent and a one year total shareholder return of minus 49.84 percent, the recent three month share price rebound of 41.14 percent suggests...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-reassessing-valuation-after-opus-phase-3-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-reassessing-valuation-after-opus-phase-3-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PCVX","LU0053671581.USD","OPUS","IE0009354923.USD","BK4139"],"gpt_icon":0},{"id":"2589358800","title":"BRIEF-Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589358800","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589358800?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:35","pubTimestamp":1765197333,"startTime":"0","endTime":"0","summary":"BRIEF-Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026Dec 8 (Reuters) - Vaxcyte Inc PCVX.O:VAXCYTE DOSES FIRST PARTICIPANTS IN THE OPUS PHASE 3, NONINFERIORITY TRIAL EVALUATING VAX-31 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUABSGKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","PCVX","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"2589261337","title":"Vaxcyte Begins Phase 3 Trial of VAX-31 Pneumococcal Vaccine in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2589261337","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589261337?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:00","pubTimestamp":1765195227,"startTime":"0","endTime":"0","summary":"Vaxcyte Inc. has announced the initiation of the OPUS Phase 3 pivotal, noninferiority clinical trial evaluating VAX-31 for the prevention of invasive pneumococcal disease  and pneumonia in adults. The trial, which aims to enroll approximately 4,000 participants, was designed in consultation with the U.S. Food and Drug Administration and will compare VAX-31 to current standard-of-care vaccines Capvaxive  and Prevnar 20 . Topline safety, tolerability, and immunogenicity results from the OPUS trial are expected in the fourth quarter of 2026. Additional Phase 3 studies are planned to begin in 2026, with results anticipated in 2027. No results from these studies have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL5Csw2v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","LU2095319765.USD","BK4139","SG9999014039.USD","IE00BGHQF748.EUR","LU0053671581.USD","SG9999014021.USD","BK4588","LU2210150020.SGD","SG9999014013.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","IE0009354923.USD","BK4112","PCVX","SG9999014005.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2589337753","title":"Vaxcyte Doses First Participants in the Opus Phase 3, Noninferiority Trial Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337753","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589337753?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:00","pubTimestamp":1765195203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUABSGKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCVX","IE0009354923.USD","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"2589337711","title":"Vaxcyte Inc - Topline Results From Opus Trial Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2589337711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589337711?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:00","pubTimestamp":1765195203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUABSGKG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","BK4139","IE0009354923.USD","PCVX"],"gpt_icon":0},{"id":"2588772529","title":"Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men","url":"https://stock-news.laohu8.com/highlight/detail?id=2588772529","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588772529?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:35","pubTimestamp":1764610500,"startTime":"0","endTime":"0","summary":"Vinay Prasad, a top regulator at the FDA, did not detail the data in the internal memo that led to the conclusion. Pfizer and BioNTech developed the COVID-19 vaccine Comirnaty.Shares of Moderna and BioNTech were down on Monday morning, likely in response to a FDA official's memo outlining a link between COVID-19 mRNA vaccines and myocarditis deaths in 10 children.Concern about that link, particularly relating to teenage boys and young men, has been a key argument against administering mRNA-based COVID vaccines in children.Vinay Prasad, the head of the Food and Drug Administration's Center for Biologics Evaluation and Research, reportedly issued a memo to staff last week that said the regulator plans to acknowledge that 10 children died after getting the vaccine. . The FDA has not publicly shared the internal research cited in the memo, although Prasad said it comes from the Vaccine Adverse Event Reporting System, which gathers reports of adverse events from the public, healthcare profe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683348.USD","BK4551","LINK.USD.HKCC","VXRT","BK4534","BK4533","LU0985481810.HKD","LU1894683264.USD","SG9999002224.SGD","IE00B19Z3B42.SGD","BK4568","SG9999003800.SGD","LU0122379950.USD","LU0170899867.USD","LU1023059063.AUD","BK4535","LU1066053197.SGD","BK4599","BK4532","SG9999001176.USD","SG9999013999.USD","MRNA","DVAX","BK4581","LU1057294990.SGD","LU0225771236.USD","SGXZ57979304.SGD","IE0002270589.USD","PCVX","IE00BBT3K403.USD","LU0058720904.USD","BK4592","IE00BLSP4452.SGD","LU0456855351.SGD","IE00BLSP4239.USD","LU0225284248.USD","LU0306806265.USD","LU0234572021.USD","LU1883839398.USD","SG9999001176.SGD","LU0321505439.SGD","BK4139","IE000M9KFDE8.USD","LU0306807586.USD","LU0053671581.USD","LU1066051498.USD","BK4585","BNTX","SG9999011175.SGD"],"gpt_icon":1},{"id":"1187950486","title":"Vaccine Stocks Falls as FDA Vows to Impose New Vaccine Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=1187950486","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187950486?lang=en_us&edition=fundamental","pubTime":"2025-12-01 23:25","pubTimestamp":1764602721,"startTime":"0","endTime":"0","summary":"Moderna Inc. fell Monday after the Food and Drug Administration said in a memo late last week it would place new restrictions on which vaccines hit the market.Vinay Prasad, a top FDA official, blamed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"de4e5ce05b2acd5962228944615f4d01","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA","BNTX","PCVX","MRK","BIIB","NVAX","AZN","VIR","HIMS","AMGN","REGN"],"gpt_icon":0},{"id":"2588720367","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2588720367","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588720367?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:02","pubTimestamp":1764594138,"startTime":"0","endTime":"0","summary":"Aditxt (ADTX) stock was down 15% pre-bell Monday, paring Friday's increase.CEA Industries (BNC) shares were 12% lower, shaving gains from the previous session.Jiayin Group (JFIN) stock was down 11% after Friday's 1% loss.Vaxcyte (PCVX) shares were 11% lower following a muted session.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PCVX","BNC","BK4139","BK4086","JFIN","ADTX","LU0053671581.USD","IE0009354923.USD","BK4166"],"gpt_icon":0},{"id":"2588727883","title":"S&P 500 Futures Fall In Premarket Trading; Vaxcyte, Cipher Mining Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727883","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727883?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:31","pubTimestamp":1764592260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, Barrick Mining Corp.  was up 4.5% in pre-market trading, and Teck Resources Ltd. Cl B  was up 3.5%.Coeur Mining Inc. , Primo Brands Corp. , and Hecla Mining Co.  were all posting gains of at least 3%. In early trading, Vaxcyte Inc.  and Cipher Mining Inc.  had posted declines, falling 10.8% and 7.4%, respectively.Meanwhile S&P 500 futures were down 0.69%, with futures for the Dow Jones Industrial Average falling 0.45%. The Cboe Volatility Index futures were down 2.93%.In commodities news, Brent crude oil futures were up 1.15%, while gold futures were up 0.81%. Bitcoin fell 5.86% to $85,986.In the previous regular trading session, the S&P 500 and the Dow were up 0.54% and 0.61%, respectively. Stocks in Asia were mixed overnight, with Japan's NIKKEI 225 Index down 1.89% and China's Shanghai Composite Index up 0.65%.U.S. stock markets open for ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345780281.USD","SDS","LU0300736492.USD","BK4600","UPRO","LU0345780950.USD","BK4581","LU0330918003.SGD","BK4595","CDE","BK4139","BK4550","IVV","OEF","ESmain","LU1223082519.USD","SPXU","BK4585","LU0345780521.USD","LU0075056555.USD","LU1023059493.AUD","LU0630314457.HKD","SPY","LU0345781412.USD","BK4210","BK4168","BK4161","BK4570","CIFR","VOO","OEX","B","BK4588","LU0053671581.USD","SSO",".SPX","LU0788109121.HKD","BK4023","LU0496367417.USD","PCVX","BK4017","LU0498741114.HKD","LU0368265764.SGD","LU1223082196.USD","PRMB","SH","BK4534","MESmain","HL","TECK"],"gpt_icon":1},{"id":"2584463918","title":"U.S. RESEARCH ROUNDUP-Amgen, Crowdstrike, Micron Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2584463918","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584463918?lang=en_us&edition=fundamental","pubTime":"2025-11-19 15:17","pubTimestamp":1763536636,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amgen, Crowdstrike, Micron TechnologyNov 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amgen,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV0GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","HD","VTVT","DKS","BK4548","SG9999015358.SGD","AMGN","ZION","WCC","INCY","BK1609","MBI","PCVX","LU0289739699.SGD","NUVB","ARWR","LU2756315664.SGD","CRWD","RAPP","FCX","TERN","DASH","LU0266013472.USD","LU0353189763.USD","PRAX","SG9999014542.SGD","LU2498475776.HKD","89888","COTY","LU0079474960.USD","BK4549","IPAR","LGIH","ENR","MU","RARE","UHS","KNTK","LU2065170008.USD","SION","ZYME","LU0820561818.USD","BRBR","LU1585245621.USD","LU0127658192.USD","OLMA"],"gpt_icon":1},{"id":"2584991650","title":"Vaxcyte Inc : Leerink Partners Raises Target Price to $77 From $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2584991650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584991650?lang=en_us&edition=fundamental","pubTime":"2025-11-19 11:56","pubTimestamp":1763524567,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WU13B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009354923.USD","BK4139","LU0053671581.USD","PCVX"],"gpt_icon":0},{"id":"2584864917","title":"Is Vaxcyte’s (PCVX) Aggressive R&D Spend Still Justified Amid Widening Losses?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584864917","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584864917?lang=en_us&edition=fundamental","pubTime":"2025-11-17 15:17","pubTimestamp":1763363850,"startTime":"0","endTime":"0","summary":"Vaxcyte, Inc. recently reported its third quarter and nine-month 2025 earnings, revealing a net loss of US$212.83 million for the quarter and US$520.12 million for the year to date, both considerably higher than the previous year’s losses.\nThe increased loss per share may draw attention to the company’s spending pace as it continues to invest in pipeline and development activities.\nWe'll examine how Vaxcyte's wider quarterly loss shapes investor perspectives on its path to future...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/is-vaxcytes-pcvx-aggressive-rd-spend-still-justified-amid-wi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/is-vaxcytes-pcvx-aggressive-rd-spend-still-justified-amid-wi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0053671581.USD","IE0009354923.USD","PCVX","BK4139"],"gpt_icon":0},{"id":"2582822070","title":"Vaxcyte Price Target Maintained With a $85.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2582822070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582822070?lang=en_us&edition=fundamental","pubTime":"2025-11-10 18:42","pubTimestamp":1762771320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PCVX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 05:42 ET (10:42 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"gpt_icon":0},{"id":"2581772964","title":"Analysts’ Top Healthcare Picks: Charles River Labs (CRL), Vaxcyte (PCVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581772964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581772964?lang=en_us&edition=fundamental","pubTime":"2025-11-06 00:20","pubTimestamp":1762359616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Charles River Labs (CRL – Research Report), Vaxcyte ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-charles-river-labs-crl-vaxcyte-pcvx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-charles-river-labs-crl-vaxcyte-pcvx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4585","CRL","LU1815336091.USD","IE0009354923.USD","LABU","BK4121","HCSG","IE00BFMHRM44.USD","BK4581","BK4588","XLV","PCVX","XBI","BK4139","BK4530","LU0029874061.USD","LU0128526141.USD","LU0053671581.USD","LU0390134368.USD","LU0757428866.USD"],"gpt_icon":0},{"id":"2581294497","title":"Needham Sticks to Its Buy Rating for Vaxcyte (PCVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581294497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581294497?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:55","pubTimestamp":1762343742,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Stringer from Needham maintained a Buy rating on Vaxcyte, with a price target of $90.00. The company’s shares cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-vaxcyte-pcvx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-vaxcyte-pcvx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PCVX"],"gpt_icon":0},{"id":"2581313711","title":"Vaxcyte, Inc. Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581313711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581313711?lang=en_us&edition=fundamental","pubTime":"2025-11-05 12:48","pubTimestamp":1762318119,"startTime":"0","endTime":"0","summary":"Vaxcyte, Inc. ( ($PCVX) ) has released its Q3 earnings. Here is a breakdown of the information Vaxcyte, Inc. presented to its investors. Vaxcyte, I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vaxcyte-inc-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vaxcyte-inc-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PCVX","LU0053671581.USD","IE0009354923.USD","BK4139"],"gpt_icon":0},{"id":"2581715347","title":"Promising Vaccine Trials and Undervaluation Drive Buy Rating for Vaxcyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2581715347","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581715347?lang=en_us&edition=fundamental","pubTime":"2025-11-05 10:55","pubTimestamp":1762311311,"startTime":"0","endTime":"0","summary":"Analyst Tara Bancroft of TD Cowen maintained a Buy rating on Vaxcyte, retaining the price target of $50.00. Tara Bancroft’s rating is based on prom...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-vaccine-trials-and-undervaluation-drive-buy-rating-for-vaxcyte-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-vaccine-trials-and-undervaluation-drive-buy-rating-for-vaxcyte-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PCVX"],"gpt_icon":0},{"id":"2581767152","title":"Vaxcyte Q3 EPS $(1.56) Misses $(1.30) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581767152","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581767152?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:47","pubTimestamp":1762292838,"startTime":"0","endTime":"0","summary":"Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.30) by 19.82 percent. This is a 87.95 percent decrease over losses of $(0.83) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48639388/vaxcyte-q3-eps-1-56-misses-1-30-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vaxcyte Q3 EPS $(1.56) Misses $(1.30) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCVX"],"gpt_icon":0},{"id":"2581798406","title":"Vaxcyte Inc: Final Data From Vax-24 Infant Phase 2 Dose-Finding Study Consistent With Previously Reported Positive Interim Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2581798406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581798406?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:05","pubTimestamp":1762290305,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA9CTWPM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PCVX","IE0009354923.USD","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"2581615147","title":"Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2581615147","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581615147?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:05","pubTimestamp":1762290300,"startTime":"0","endTime":"0","summary":"Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180843/0/en/Vaxcyte-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update-Including-Final-Data-from-Positive-VAX-24-Infant-Phase-2-Dose-Finding-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4208","BK4139","PCVX","STRK","BK4023","BK4595","BK4600","BK4596","LU0053671581.USD","BK4588","NI","BK4585","BK4516","IE0009354923.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.vaxcyte.com","stockEarnings":[{"period":"1week","weight":-0.0321},{"period":"1month","weight":-0.0234},{"period":"3month","weight":0.3861},{"period":"6month","weight":0.2902},{"period":"1year","weight":-0.5103},{"period":"ytd","weight":-0.4553}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1544},{"period":"1year","weight":0.1345},{"period":"ytd","weight":0.1759}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.022898},{"month":2,"riseRate":0.4,"avgChangeRate":-0.011769},{"month":3,"riseRate":0.2,"avgChangeRate":-0.152425},{"month":4,"riseRate":0.4,"avgChangeRate":-0.015793},{"month":5,"riseRate":0.6,"avgChangeRate":0.069759},{"month":6,"riseRate":0.8,"avgChangeRate":0.011811},{"month":7,"riseRate":0.5,"avgChangeRate":0.011479},{"month":8,"riseRate":0.833333,"avgChangeRate":0.13264},{"month":9,"riseRate":0.5,"avgChangeRate":0.090313},{"month":10,"riseRate":0.333333,"avgChangeRate":0.104582},{"month":11,"riseRate":0.5,"avgChangeRate":-0.025818},{"month":12,"riseRate":0.5,"avgChangeRate":0.00261}],"exchange":"NASDAQ","name":"Vaxcyte, Inc.","nameEN":"Vaxcyte, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vaxcyte, Inc.(PCVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vaxcyte, Inc.(PCVX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vaxcyte, Inc.,PCVX,Vaxcyte, Inc.股票,Vaxcyte, Inc.股票老虎,Vaxcyte, Inc.股票老虎国际,Vaxcyte, Inc.行情,Vaxcyte, Inc.股票行情,Vaxcyte, Inc.股价,Vaxcyte, Inc.股市,Vaxcyte, Inc.股票价格,Vaxcyte, Inc.股票交易,Vaxcyte, Inc.股票购买,Vaxcyte, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vaxcyte, Inc.(PCVX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vaxcyte, Inc.(PCVX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction